BSLN — Basilea Pharmaceutica AG Allschwil Cashflow Statement
0.000.00%
Last trade - 00:00
- CH₣550.30m
- CH₣583.02m
- CH₣157.63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -22.4 | -14.7 | -6.83 | 12.1 | 10.5 |
Depreciation | |||||
Non-Cash Items | 3.81 | -9.84 | 5.84 | 4.09 | 6.21 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -46.9 | -30.8 | -31.8 | -10.3 | -3.99 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -63.8 | -54.1 | -32 | 7.06 | 14.2 |
Capital Expenditures | -0.404 | -2.27 | -0.86 | -3.3 | -1.03 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | -32.7 | 4.43 | 95 | 0 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.404 | -35 | 3.58 | 91.6 | -1.03 |
Financing Cash Flow Items | — | -3.19 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.31 | 45.1 | 16.6 | -45.2 | -57.3 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -62.9 | -44.8 | -11.3 | 53.6 | -44.2 |